facilities, are not standardized in form, and are collected with the expectation that a human being (such as another clinician), rather than an automated system, will read the information in the record. Therefore, it can be difficult to extract phenotypic information from electronic medical record data.
To partially address these challenges, Denny et al. 2 created shareable and potentially reusable phenotype descriptions primarily comprising codes from the International Classification of Disease, ninth revision, Clinical Modification (ICD9). ICD9 codes are alphanumeric codes corresponding to the diagnoses and procedures recorded in conjunction with a doctor visit and are used primarily for billing. To expand the list of PheWAS phenotypes beyond those used in their earlier work 1 , and in an effort to extract fine-grained NHGRI GWAS phenotypes from electronic medical record data, Denny et al. 2 included additional types of codes and created a hierarchy of phenotypes (e.g., introducing inflammatory bowel disease as a parent phenotype for Crohn's disease and ulcerative colitis). Although other items from an electronic medical record could potentially be used (e.g., text mentions, laboratory results and medical orders), the authors chose to define the phenotypes as ICD9 codes because these codes are the most universally available form of electronic medical record data. The phenotype definitions created by Denny et al. 2 should be useful to others seeking to conduct PheWAS or to refine phenotype descriptions by including additional data items from the electronic medical record.
To test each SNP-phenotype association, the authors identified the number of patients who had the phenotype (defined as having two distinct instances of the relevant ICD9 code) and the suitable controls (those that did not have the ICD9 codes corresponding to the phenotype). Patients with only one occurrence of the ICD9 code were excluded from the analysis. The strength of the association between the in electronic medical records, it offers a strategy for mining data generated in routine clinical practice.
The new report by Denny et al. 2 is more ambitious than previous PheWAS. Rather than studying a handful of genetic variants, the authors analyzed associations between a large number of variants and a large number of phenotypes-3,144 single-nucleotide polymorphisms (SNPs) and 1,358 phenotypes extracted from electronic medical records-thereby allowing associations to be discovered in an unbiased manner (Fig. 1b) . Moreover, they systematically compared the associations produced by the PheWAS with those in the National Human Genome Research Institute (NHGRI)'s GWAS Catalog, a repository for GWAS data.
The population studied by Denny et al. 2 consisted of 13,835 individuals of European descent whose samples and associated electronic medical records were available through the Electronic Medical Records and Genomic (eMERGE) Network. Funded by NHGRI, eMERGE is a national consortium designed to create, share and apply approaches to integrate DNA biorepositories with electronic medical record systems, with the ultimate goal of extracting genomic testing results and providing them to patients in a clinical care setting. To enable comparison with GWAS data, the authors restricted their analysis to SNPs in the NHGRI GWAS Catalog. At the beginning of their study, the catalog contained 6,092 SNPs. Of these, 3,144 were present and passed quality control on the Illumina chip that the authors used for genotyping. After applying a commonly accepted cut-off for genome-wide significance of P ≤ 5 × 10 −8 , the authors narrowed down the 3,144 SNPs to 673-or 751 SNP-phenotype associations-which they went on to compare with the results of PheWAS.
Electronic medical records are generated as a by-product of health care rather than for research as the primary goal. Data are collected when a patient is ill, are split across visits and
The phenome-wide association study (PheWAS) is a relatively new approach for exploring the influence of genetic variation on disease etiology. First described by Denny et al. 1 in 2010, PheWAS involves searching for associations between genetic variants and a wide spectrum of disease phenotypes, typically captured in electronic medical records or epidemiologic studies. But how reliable are the resulting associations? In a report in this issue, Denny et al. 2 sought to validate PheWAS by comparing the associations it discovers to those identified by genome-wide association studies (GWAS). Notably, they find that a single PheWAS replicates 66% of the associations produced by multiple GWAS studies that were sufficiently powered. Moreover, PheWAS reveals new and potentially pleiotropic associations that could not have been readily identified by GWAS.
A GWAS usually starts with a phenotype chosen by the investigator and searches the genome for associated genetic variants. In contrast, PheWAS begins with genetic variants and looks for associations with a large collection of disease phenotypes (Fig. 1a) . Previous PheWAS papers have studied a small number of genetic variants: two began with a genomic region of interest (e.g., HLA-DRB1*1501 and FOXE1) and searched for associated phenotypes 3, 4 , and two others began with a phenotype of interest (e.g., platelet count and rheumatoid arthritis), searched for associated genetic markers and then performed a PheWAS to identify pleiotropic associations of those genetic markers with other phenotypes 5, 6 .
Because PheWAS can detect multiple, seemingly unrelated phenotypes associated with a single genetic variant, it facilitates the identification of pleiotropic associations. And because it can make use of information buried
Mining the ultimate phenome repository
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Combining genotyping and the data locked in medical records yields a large number of known genotypephenotype associations.
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Denny et al. 2 found that PheWAS replicated 210 of the 751 SNP-phenotype associations from the NHGRI GWAS Catalog. To determine why not all associations were replicated, they filtered the 751 associations according to three criteria: the statistical power of the original study, the number of independent studies that reported the association, and whether the GWAS trait exactly matched the electronic medical record phenotype used for PheWAS. The likelihood of replication increased proportionally with the statistical power of the original GWAS study, the number of independent GWAS studies reporting the association, and the degree of match between GWAS and electronic medical record traits. After adjusting for these factors, they concluded that PheWAS replicated 51 of 77 associations (66%).
Notably, PheWAS also identified 63 electronic medical record trait-genotype associations that are not included in the NHGRI GWAS Catalog and are potentially novel. Further study replicated two of these new associations in an independent patient cohort. In fact, during the validation process, the authors also expanded their phenotype definitions to include text mentions in the electronic medical record identified by natural language processing.
The main advantage of PheWAS-the ability to search for associations between SNPs and a large number of phenotypes-also results in its main limitation, namely, the potential for high false-positive rates. Denny et al. 2 controlled for such false discovery by adjusting the P-value cutoff to allow for 10% false discovery rate. Adjusting the P-value for an acceptable false discovery rate is better than a simple Bonferroni correction, which would divide the traditional P-value cutoff of 0.05 by the number of associations tested. Naturally, a statistical correction is no guarantee that the false discovery rate is truly 10%. It may be possible to create a ground-truth data set with known negative associations, which in conjunction with the known positive associations from GWAS could be used to quantify the actual false discovery rate for a high-throughput PheWAS study.
Electronic medical records are increasing at a rapid pace and represent the ultimate repository of disease-phenotype information. According to the Office of the National Coordinator for Health Information Technology, hospital adoption of electronic medical record systems has grown from 12% to 44% since 2009. Electronic medical record adoption by family physicians is estimated to exceed 80% by the end of 2013.
One important application of electronic medical record data is for genetics research, as in the PheWAS of Denny et al. 2 . In another notable instance, Blair et al. 7 used the medical records of >110 million patients to find reproducible patterns linking complex disorders to unique collections of Mendelian loci. But the utility of electronic medical records extends well beyond genetics. For example, phenotyping for clinical research, particularly drug safety research and patient-centered outcomes research, is already underway. The FDA's Sentinel initiative, launched in 2008 to track the safety of drugs, biologics and medical devices using electronic health record systems, administrative and claims databases, and registries, already analyzes data from over 100 million patients (http://www.mini-sentinel. org/). The recently launched National PatientCentered Clinical Research Network (http:// www.pcori.org/funding-opportunities/ improving-our-national-infrastructure-toconduct-comparative-effectiveness-research) aims to build national capacity to conduct comparative effectiveness research using data from electronic medical records.
Eventually, electronic medical record data might help to bridge the 'evidence gap'-the gap between the evidence needed to support care decisions and the evidence produced by randomized controlled trials -which was highlighted in a recent report by the Institute of Medicine. It may be possible to 'learn' physician practice patterns from the record of routine clinical practice embedded in electronic medical records, thereby generating practice-based evidence 8 . 2 test many genetic variants against many phenotypes extracted from electronic medical records to validate PheWAS and to make new discoveries. Note that not all phenotypes can be reliably extracted from electronic medical record data.
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Robust descriptions of phenotypes (referred to as 'health outcomes of interest' in some research communities) would allow full exploitation of data already collected in electronic medical records to advance the genomic understanding of disease, to improve clinical practice 8, 9 and to make discoveries through clinical data mining. The work of Denny et al. 2 to generate reusable, accurate and unambiguous descriptions of health outcomes or phenotypes is an important step toward this goal.
More generally, electronic medical record-based phenotyping has the potential to provide a link between studies that advance the science of medicine (e.g., PheWAS) and studies that advance the practice of medicine 9 . But achieving this will require reliable methods of 'electronic pheno typing' that allow unambiguous recognition of disease conditions or traits from electronic medical record data. This would mean mining not only ICD9 codes but also mentions in textual notes, expected laboratory test values and drug prescriptions. As part of the eMERGE Network, Denny and others have already begun a collaboration to create the Phenome Knowledge Base (PheKB; http://www.phekb.org/). This resource provides an anchor for a community interested in building and validating methods for electronic medical record-based phenotyping 10 . PheKB already lists phenotyping methods that go beyond billing codes and text-mentions, and presents algorithms able to extract 21 different phenotypes and/or diseases from electronic medical record data.
Epigenome editing
Philipp voigt & danny Reinberg
Technologies developed for genome editing are repurposed to study functions of chromatin modifications. with a guide RNA that recruits the nuclease to complementary DNA sequences 6 .
Nucleases are not the only proteins that can be targeted to specific loci. TALE and zinc finger proteins have been fused to transcriptional activators such as the VP16 protein of herpes simplex virus and transcriptional repressors such as the Krüppel-associated box (KRAB) domain of the transcription factor Kox1 (ref. 4) . By fusing TALEs to chromatin modifiers, the three new studies [1] [2] [3] are the first to use TALEs for locus-specific editing of the epigenome rather than the genome.
Even though comparisons of genomewide maps of epigenetic modifications and gene expression data have been invaluable in ascribing activating or repressive functions to specific modifications, most insights into epigenetic mechanisms stem from in vitro biochemical and structural analyses. Knockout studies in model organisms have clarified the role of many chromatin factors, revealing, for example, how they influence transcription in the context of developmental processes. However, knockout of a chromatin modifier leads to genome-wide changes, whereas many modifications occur in different contexts, and it is often desirable to probe the function of a modification only in one specific setting. For example, DNA methylation occurs at repeat regions, promoters, enhancers, insulators and gene bodies 7 ; despite generally correlating with gene repression, DNA methylation in gene bodies has been implicated in splicing of transcribed genes 7 . To unravel such potentially divergent functions at different regions requires targeted alteration of DNA methylation status. Moreover, targeted interventions would be tremendously helpful to better connect biochemical insights about histone modifications with cellular consequences. That is, effects at single genes or parts of genes could be studied without the confounding, secondary effects that can arise in knockouts. Furthermore, many chromatin-modifying complexes might have functions independent of their direct effects on chromatin modifications, and so specific removal of the modification while leaving the complex intact may provide a way of separating the catalytic and noncatalytic effects of a complex.
The chromatin-modifying activity studied by Maeder et al. 1 was removal of DNA methylation from specific CpG sites in human cell lines. They fused TALEs to the catalytic domain of ten-eleven translocation 1 (TET1), a member of a family of proteins that oxidize 5-methyl cytosine (5mC) to 5-hydroxymethylcytosine and thereby initiate demethylation 8 (Fig. 1a) . Using TALEs designed to bind sites within the human KLF4, powerful new tools to activate or repress specific genes and, perhaps more importantly, to analyze directly how individual chromatin modifications control chromatin states and gene expression.
Genome editing technology has relied on a handful of DNA-binding proteins, primarily TALEs and zinc finger proteins, that can be engineered to target sequences of interest 5 . When coupled to nucleases, these proteins allow double-strand breaks to be introduced at specific loci. The breaks are repaired either through nonhomologous end joining, which leads to insertion or deletion mutations that can disrupt the target gene, or through homologous recombination, which permits insertion of exogenously supplied sequences. The modular structure of TALEs and the known base specificity of individual repeat domains make it straightforward to design TALEs that target a chosen location in a genome. Recently, an even more tractable system has been developed based on a bacterial Cas9 nuclease in complex Genome-scale epigenetic maps have been generated for many different cell types and organisms and have yielded important biological insights, but such data are largely correlative. A crucial challenge in epigenetics is determining the precise roles of specific DNA or histone modifications. Two studies in this issue 1,2 and one published recently in Nature 3 show that epigenetic marks can be modified at a specific genomic locus, enabling fine-grained study of their activity. All three groups achieve this longawaited goal using customizable transcription activator-like effector (TALE) proteins 4 previously applied to editing the genome-to recruit chromatin-modifying enzymes to specific loci. These studies introduce N e W S A N D v I e W S npg
